Beam Therapeutics: Pay

Beam Therapeutics paid its 5 named executives $15.0M in total in FY2025 (Dec). CEO John Evans was paid $5.8M of that.

Pay$100 in the stock at the end of FY20 → $34
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

John EvansCEO
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years
Giuseppe Ciaramella, Ph.D.President
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years
Sravan EmanyCFO
FY2025 (Dec)
FY2024 (Dec)
2 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 4 peers with pay on file was $6.5M. The CEO of Beam Therapeutics was paid $5.8M, 11% below the median.

  1. 1BridgeBio Pharma
  2. 2CRISPR Therapeutics AG
  3. 3Beam Therapeutics
  4. 4Agios Pharmaceuticals
  5. 5Denali Therapeutics
  6. 6Apellis Pharmaceuticals, Inc.Not disclosed
  7. 7Arcellx, Inc.Not disclosed
  8. 8Arrowhead PharmaceuticalsNot disclosed
  9. 9Blueprint Medicines CorporationNot disclosed
  10. 10Editas Medicine, Inc.Not disclosed
  11. 11ImmunityBio, Inc.Not disclosed
  12. 12Intellia Therapeutics, Inc.Not disclosed
  13. 13Iovance Biotherapeutics, Inc.Not disclosed
  14. 14Prime Medicine, Inc.Not disclosed
  15. 15Rocket Pharmaceuticals, Inc.Not disclosed
  16. 16Sana Biotechnology, Inc.Not disclosed
  17. 17Verve Therapeutics, Inc.Not disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.